Incorporation of nitroprusside on silica nanoparticles - a strategy for safer use of this NO donor in therapy
Molecular pharmaceutics | 16 May 2019
PM Silva Filho, IA Paz, NRF Nascimento, CF Santos, VR Araujo, CP Aquino, TS Ribeiro, IF Vasconcelos, LG de França Lopes, EHS Sousa and E Longhinotti
Silica-based nanoparticles have been developed as powerful platforms for drug delivery, which might also prevent undesired side effects of drugs. Here, a fast method to synthetize a positively charged mesoporous silica nanoparticles (ζ = 20 ± 0.5 mV, surface area = 678 m2 g-1 and 2.3 nm of porous size) was reported. This nanomaterial was employed to anchor sodium nitroprusside (SNP), a vasodilator drug with undesired cyanide release. A remarkable incorporation of 323.9 ± 7.55 μmol of SNP per gram of nanoparticle was achieved, and a series of studies of NO release were conducted, showing efficient release of NO along with major cyanide retention (ca. 64 % bound to nanoparticle). Biological assays with mammalian cells showed only a slight drop in cell viability (13 %) at the highest concentration (1000 μM), while SNP exhibited LC50 of 228 μM. Moreover, pharmacological studies demonstrated similar efficacy for vasodilation and sGC-PKG-VASP pathway activation when compared to SNP alone. Altogether, this new SNP silica-nanoparticle has great potential as an alternative for wider and safer use of SNP in medicine with lower cyanide toxicity.
* Data courtesy of Altmetric.com